

Please replace the Abstract of the Disclosure with the following rewritten paragraph:

02
-- Flt3-ligand has been shown to generate large numbers of dendritic cells from hematopoietic progenitor and stem cells. In this regard, flt3-ligand can be used to augment immune responses to cancerous and neoplastic disease when administered in combination with other reactive agents, e.g. CD40 binding proteins, 4-1BBL or antibodies reactive with 4-1BB, CD30 ligand antagonists, RANKL, and/or interferon alpha. Such combination therapy may also be used to enhance immune responses to vaccine antigens.

In the Claims:

Kindly add the following new claims:

03
-- 15. (New) A method according to claim 1, wherein the one or more compounds are administered in a sequential or concurrent combination with flt3-ligand. --

-- 16. (New) A method according to claim 2, wherein the CD40 binding protein, antibody reactive with 4-1BB, 4-1BB-L, interferon alpha, RANKL, CD30 ligand antagonists, GM-CSF, IL-4, TNF- α , IL-3, c-kit ligand, and fusions of GM-CSF and IL-3 are administered in a sequential or concurrent combination with flt3-ligand. --

-- 17. (New) A method according to claim 14, further comprising the step of administering one or more of the molecules selected from the group consisting of GM-CSF, IL-4, TNF- α , IL-3, c-kit ligand, and fusions of GM-CSF and IL-3. --

-- 18. (New) A method according to claim 6, wherein there is a reduction in tumor growth in the patient. --

-- 19. (New) A method according to claim 6, wherein there is a reduction in tumor incidence in the patient.. --

-- 20. (New) A method according to claim 6, wherein there is an increase in tumor rejection in the patient. --

-- 21. (New) A method according to claim 6, wherein flt3-ligand and CD40 binding protein are administered in amounts sufficient to induce expression of IL-12 in tumors of the patient.

--